The dollar has slipped to new lows against its major peers in the past 24 hours amid some slightly downbeat US economic data and growing optimism surrounding a number of COVID-19 vaccines. Versus the euro, the greenback is currently trading around its weakest positions since the beginning of September, and not far off its lowest level since May 2018. The US is expected to be one of the main beneficiaries of the COVID vaccine from Pfizer and BioNTech, which earlier this month stated that its creation had yielded a 95% effectiveness against the virus in the final stages of testing. While the dollar received decent support from the news, sentiment towards the currency has since soured slightly, as investors have instead begun favouring risky currencies in the hope that the vaccines could allow economic activity to return to more normal levels by spring next year. We also had a slew of macroeconomic data out of the US on Wednesday, most of which missed its mark. Initial jobless claims jumped up to a five-week high, new homes sales unexpectedly contracted, while personal income also fell in the month to October. There is general acknowledgement that the situation for the US economy could be about to worsen before it gets better. New COVID-19 cases jumped to a daily record above 200,000 last week, with deaths yesterday rising to their highest level since early-May. A stricter reimposition of lockdown measures may well be forthcoming in many states in the coming days, which does present a bit of downside risk to the dollar. Last night’s dovish FOMC meeting minutes also far from helped the currency.
